Topics

Laboratorios Farmacéuticos ROVI - Multiple growth drivers lie ahead

04:58 EST 4 Dec 2019 | FinanzNachrichten

Following Laboratorios Farmacéuticos ROVI's (ROVI's) recent investor day, we have reviewed our near-term forecasts. Specifically, we upgrade our Becat (enoxaparin biosimilar) peak sales forecasts a...

Original Article: Laboratorios Farmacéuticos ROVI - Multiple growth drivers lie ahead

NEXT ARTICLE

More From BioPortfolio on "Laboratorios Farmacéuticos ROVI - Multiple growth drivers lie ahead"

Quick Search

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...